<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38724010</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Association between combination COVID-19-influenza vaccination and long COVID in middle-aged and older Europeans: A cross-sectional study.</ArticleTitle><Pagination><StartPage>2345505</StartPage><MedlinePgn>2345505</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2345505</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2024.2345505</ELocationID><Abstract><AbstractText>The potential impact of combined COVID-19 and influenza vaccination on long COVID remains uncertain. In the present cross-sectional study, we aimed to investigate the plausible association between them in middle-aged and older Europeans based on the Survey of Health, Ageing, and Retirement in Europe (SHARE). A total of 1910 participants were recruited in the analyses. The study outcome was long COVID. Participants were divided into 4 groups through the self-reported status of COVID-19 and influenza vaccination. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated. 1397 participants experienced long COVID. After multivariable adjustment, those vaccinated with neither COVID-19 nor influenza vaccine had higher risk of long COVID (OR, 1.72; 95% CI, 1.26-2.35) compared to those vaccinated with both vaccines. Furthermore, adding the 4 statuses of COVID-19 vaccination/influenza vaccination to conventional risk model improved risk reclassification for long COVID (continuous net reclassification improvement was 16.26% [<i>p</i>&#x2009;=&#x2009;.003], and integrated discrimination improvement was 0.51% [<i>p</i>&#x2009;=&#x2009;.005]). No heterogeneity was found in the subgroup analyses (all <i>p</i>-interaction &#x2265;0.05). Our study might provide a strategy for people aged 50 and over to reduce the occurrence of long COVID, that is, to combine the use of the COVID-19 vaccine and influenza vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Wenyan</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center of Clinical Laboratory, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xiaowei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Public Health Research Center and Department of Public Health and Preventive Medicine, Wuxi School of Medicine Jiangnan University, Wuxi, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Chronic Infectious Disease Control, Wuxi Center for Disease Control and Prevention, The Affiliated Wuxi Center for Disease Control and Prevention of Nanjing Medical University,Wuxi, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miao</LastName><ForeName>Tongtong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Nantong First People's Hospital, Second Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zang</LastName><ForeName>Yuhan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Health Promotion and Chronic Non-Communicable Disease Control, Wuzhong Center for Disease Control and Prevention, Suzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Suwen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Administration, Suzhou Industrial Park Medical and Health Management Center, Suzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Yumeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Acute Infectious Disease Control, The Affiliated Wuxi Center for Disease Control and Prevention of Nanjing Medical University, Wuxi, Jiangsu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094854" MajorTopicYN="N">European People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">Survey of Health, Ageing, and Retirement in Europe</Keyword><Keyword MajorTopicYN="N">combined use</Keyword><Keyword MajorTopicYN="N">influenza vaccine</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>10</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>10</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>9</Day><Hour>19</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38724010</ArticleId><ArticleId IdType="pmc">PMC11085989</ArticleId><ArticleId IdType="doi">10.1080/21645515.2024.2345505</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . 2023.  [accessed 2023 Nov
8]. https://covid19.who.int/.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ.. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;7. doi:10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S, Li Y, Wang L, Zhao X, Ma X, Gao GF. Assessment of vaccinations and breakthrough infections after adjustment of the dynamic zero-COVID-19 strategy in China: an online survey. Emerg Microbes Infect. 2023;12(2):2258232. doi:10.1080/22221751.2023.2258232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2023.2258232</ArticleId><ArticleId IdType="pmc">PMC10512888</ArticleId><ArticleId IdType="pubmed">37691586</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips S, Williams MA. Confronting our next national health disaster - Long-Haul Covid. N Engl J Med. 2021;385(7):577&#x2013;9. doi:10.1056/NEJMp2109285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2109285</ArticleId><ArticleId IdType="pubmed">34192429</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, Huggins CF, Kwong ASF, Silverwood RJ, Di Gessa G. et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13(1):3528. doi:10.1038/s41467-022-30836-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30836-0</ArticleId><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi-Pooya AA, Akbari A, Emami A, Lotfi M, Rostamihosseinkhani M, Nemati H, Barzegar Z, Kabiri M, Zeraatpisheh Z, Farjoud&#x2010;Kouhanjani M. et al. Long COVID syndrome-associated brain fog. J Med Virol. 2022;94(3):979&#x2013;84. doi:10.1002/jmv.27404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27404</ArticleId><ArticleId IdType="pmc">PMC8662118</ArticleId><ArticleId IdType="pubmed">34672377</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme M, Braillard O, Salamun J, Jacquerioz F, Courvoisier DS, Spechbach H, Guessous I. Symptoms after COVID-19 vaccination in patients with post-acute sequelae of SARS-CoV-2. J Gen Intern Med. 2022;37(6):1585&#x2013;8. doi:10.1007/s11606-022-07443-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07443-2</ArticleId><ArticleId IdType="pmc">PMC8863092</ArticleId><ArticleId IdType="pubmed">35194744</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao P, Liu J, Liu M. Effect of COVID-19 vaccines on reducing the risk of long COVID in the real world: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(19):12422. doi:10.3390/ijerph191912422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191912422</ArticleId><ArticleId IdType="pmc">PMC9566528</ArticleId><ArticleId IdType="pubmed">36231717</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin-Hernandez D, Schwartz RE, Nixon DF. Epidemiological evidence for association between higher influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy. J Med Virol. 2021;93(1):64&#x2013;5. doi:10.1002/jmv.26120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26120</ArticleId><ArticleId IdType="pmc">PMC7300995</ArticleId><ArticleId IdType="pubmed">32497290</ArticleId></ArticleIdList></Reference><Reference><Citation>Conlon A, Ashur C, Washer L, Eagle KA, Hofmann Bowman MA. Impact of the influenza vaccine on COVID-19 infection rates and severity. Am J Infect Control. 2021;49(6):694&#x2013;700. doi:10.1016/j.ajic.2021.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2021.02.012</ArticleId><ArticleId IdType="pmc">PMC7899024</ArticleId><ArticleId IdType="pubmed">33631305</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CH, Pinho MP, Buckley PR, Woodhouse IB, Ogg G, Simmons A, Napolitani G, Koohy H.. Potential CD8+ T cell cross-reactivity against SARS-CoV-2 conferred by other coronavirus strains. Front Immunol. 2020;11:579480. doi:10.3389/fimmu.2020.579480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.579480</ArticleId><ArticleId IdType="pmc">PMC7676914</ArticleId><ArticleId IdType="pubmed">33250893</ArticleId></ArticleIdList></Reference><Reference><Citation>Stowe J, Tessier E, Zhao H, Guy R, Muller-Pebody B, Zambon M, Andrews N, Ramsay M, Lopez Bernal J. Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design. Int J Epidemiol. 2021;50(4):1124&#x2013;33. doi:10.1093/ije/dyab081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyab081</ArticleId><ArticleId IdType="pmc">PMC8135706</ArticleId><ArticleId IdType="pubmed">33942104</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance, https://apps.who.int/iris/handle/10665/346897;
2021.  [accessed on 8
November 2023].</Citation></Reference><Reference><Citation>Janssen C, Mosnier A, Gavazzi G, Combadi&#xe8;re B, Cr&#xe9;pey P, Gaillat J, Launay O, Botelho-Nevers E. Coadministration of seasonal influenza and COVID-19 vaccines: a systematic review of clinical studies. Hum Vaccin Immunother. 2022;18(6):2131166. doi:10.1080/21645515.2022.2131166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2131166</ArticleId><ArticleId IdType="pmc">PMC9746457</ArticleId><ArticleId IdType="pubmed">36256633</ArticleId></ArticleIdList></Reference><Reference><Citation>Borsch-Supan A, Brandt M, Hunkler C, Kneip T, Korbmacher J, Malter F, Schaan B, Stuck S, Zuber S. Data resource profile: the survey of health, ageing and retirement in Europe (SHARE). Int J Epidemiol. 2013;42(4):992&#x2013;1001. doi:10.1093/ije/dyt088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyt088</ArticleId><ArticleId IdType="pmc">PMC3780997</ArticleId><ArticleId IdType="pubmed">23778574</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;rsch-Supan A. Survey of health, ageing and retirement in Europe (SHARE) wave 8. Release version: 8.0.0. SHARE-ERIC. Data set; 2022. doi:10.6103/SHARE.w8.800.</Citation><ArticleIdList><ArticleId IdType="doi">10.6103/SHARE.w8.800</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;rsch-Supan A. Survey of health, ageing and retirement in Europe (SHARE) wave 8. COVID-19 survey 1. Release version: 8.0.0. SHARE-ERIC. Data set; 2022. doi:10.6103/SHARE.w8ca.800.</Citation><ArticleIdList><ArticleId IdType="doi">10.6103/SHARE.w8ca.800</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;rsch-Supan A. Survey of health, ageing and retirement inEurope (SHARE) wave 9. COVID-19 survey 2. Release version: 8.0.0. SHARE-ERIC. Data set; 2022. doi:10.6103/SHARE.w9ca.800.</Citation><ArticleIdList><ArticleId IdType="doi">10.6103/SHARE.w9ca.800</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . A clinical case definition of post COVID-19 condition by a Delphi consensus; 2021 Oct6 [accesssed 2024 Apr7]. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, Ward H, Elliott P. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022;13(1):1957. doi:10.1038/s41467-022-29521-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29521-z</ArticleId><ArticleId IdType="pmc">PMC9005552</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk P, Moran V, Alperin MNP, Bohn T, Fagherazzi G, Zeegers MP, Ruiz-Castell M. The role of multimorbidity and socio-economic characteristics as potential risk factors for long covid: evidence from the multilevel analysis of the survey of health, ageing and retirement in Europe&#x2019;s corona surveys (2020&#x2013;2021). Age Ageing. 2023;52(12):afad225. doi:10.1093/ageing/afad225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afad225</ArticleId><ArticleId IdType="pmc">PMC10733586</ArticleId><ArticleId IdType="pubmed">38124254</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince MJ, Reischies F, Beekman AT, Fuhrer R, Jonker C, Kivela SL, Lawlor BA, Lobo A, Magnusson H, Fichter M. et al. Development of the EURO&#x2013;D scale &#x2013; a European union initiative to compare symptoms of depression in 14 European centres. Br J Psychiatry. 1999;174(4):330&#x2013;8. doi:10.1192/bjp.174.4.330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.174.4.330</ArticleId><ArticleId IdType="pubmed">10533552</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong C, Wang G, Xu T, Zhu Z, Guo D, Zheng X, Wang A, Bu X, Peng H, Chen J. et al. Tissue inhibitor metalloproteinase-1 and clinical outcomes after acute ischemic stroke. Neurology. 2019;93(18):1675&#x2013;85. doi:10.1212/WNL.0000000000008389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008389</ArticleId><ArticleId IdType="pubmed">31551260</ArticleId></ArticleIdList></Reference><Reference><Citation>Pencina MJ, D&#x2019;Agostino RB Sr., D&#x2019;Agostino RB Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157&#x2013;72. discussion 207-112. doi: 10.1002/sim.2929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2929</ArticleId><ArticleId IdType="pubmed">17569110</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022;103:154&#x2013;62. doi:10.1016/j.bbi.2022.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2022.04.013</ArticleId><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461&#x2013;7. doi:10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, Peligro PJ, Casimiro M, Guerrero JJ, Gellaco MML. et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine. 2022;53:101624. doi:10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, Rescigno M. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA. 2022;328(7):676&#x2013;8. doi:10.1001/jama.2022.11691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Tofarides AG, Christaki E, Milionis H, Nikolopoulos GK. Effect of vaccination against SARS-CoV-2 on long COVID-19: a narrative review. Life (Basel). 2022;12(12):2057. doi:10.3390/life12122057.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12122057</ArticleId><ArticleId IdType="pmc">PMC9785763</ArticleId><ArticleId IdType="pubmed">36556422</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH, Santillana M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, Green J, Quintana A, Druckman J, Baum MA. et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open. 2022;5(10):e2238804. doi:10.1001/jamanetworkopen.2022.38804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.38804</ArticleId><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Veronese N, Smith L, Di Gennaro F, Bruy&#xe8;re O, Yang L, Demurtas J, Maggi S, Sabico S, Al-Daghri NM, Barbagallo M. et al. Influenza vaccination and COVID-19 outcomes in people older than 50 years: data from the observational longitudinal SHARE study. Vaccines. 2022;10(6):899. doi:10.3390/vaccines10060899.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060899</ArticleId><ArticleId IdType="pmc">PMC9229857</ArticleId><ArticleId IdType="pubmed">35746506</ArticleId></ArticleIdList></Reference><Reference><Citation>Debisarun PA, Struycken P, Dom&#xed;nguez-Andr&#xe9;s J, Moorlag SJCFM, Taks E, Gssling KL, Ostermann PN, M&#xfc;ller L, Schaal H, Oever JT, et al. The effect of influenza vaccination on trained immunity: impact on COVID-19. medRxiv. 2020. doi:10.1101/2020.10.14.20212498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.14.20212498</ArticleId></ArticleIdList></Reference><Reference><Citation>Benn CS, Netea MG, Selin LK, Aaby P. A small jab - a big effect: nonspecific immunomodulation by vaccines. Trends Immunol. 2013;34(9):431&#x2013;9. doi:10.1016/j.it.2013.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2013.04.004</ArticleId><ArticleId IdType="pubmed">23680130</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortona E, Malorni W. Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for tailored therapy. Eur Respir J. 2022;59(2):2102245. doi:10.1183/13993003.02245-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02245-2021</ArticleId><ArticleId IdType="pmc">PMC8462012</ArticleId><ArticleId IdType="pubmed">34531277</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>